pSivida Announces Positive Results From The Two Phase 3 FAME™ Trials of Iluvien in Patients With Diabetic Macular Edema

pSivida Corp., a sustained release drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back of the eye diseases, recently reported top-line 24 month results from the Phase III FAME™ study of Iluvien® for the treatment of Diabetic Macular Edema (DME) being conducted by pSivida’s collaborative partner Alimera Sciences.

More patients receiving either the High Dose or Low Dose Iluvien showed improvement in best corrected visual acuity of 15 or more letters at 2 years compared to those receiving sham treatment.

pSivida’s licensee, Alimera Sciences, plans to file New Drug Application (NDA) in the second quarter of 2010.